Back to Results
First PageMeta Content
ATryn / Anticoagulants / Genetic engineering / Goats / Medicine / Clinical research / Biopharmaceutical / Monoclonal antibodies / Antithrombin / Biotechnology / Biology / Pharmacology


Paris, 19 MayPress releaseGTC BIOTHERAPEUTICS Inc., a LFB group company, granted protection until 2027 on broad transgenic protein production patent, and is also granted new patent on recombinant antithrombin pro
Add to Reading List

Document Date: 2012-08-14 05:05:18

Open Document

File Size: 34,51 KB

Share Result on Facebook

City

Les Ulis / Paris / /

Company

LFB Biotechnologies S.A.S. / GTC BIOTHERAPEUTICS GTC / GTC Biotherapeutics Inc. / LFB Group / Press releaseGTC BIOTHERAPEUTICS Inc. / /

Continent

Europe / /

Country

France / United States / /

Currency

EUR / /

/

Event

Patent Issuance / FDA Phase / /

IndustryTerm

biopharmaceutical / treatment of serious and often rare diseases / therapeutic proteins / therapeutic product / transgenic animal technology / plasma-derived medicinal products / recombinant production systems / biopharmaceutical industry / medicinal products / health technologies / /

MedicalCondition

often rare diseases / III deficiency / inflammation / /

MedicalTreatment

innovative therapies / /

Organization

EMA / United States Patent and Trademark Office / FDA / /

Person

William Heiden / Christian Bechon / /

/

Position

CEO / leader / Director of Communication Tel / /

Product

S.A.S / ATryn® / /

Technology

transgenic protein production / transgenic animal technology / health technologies / antibodies / medicinal products / /

URL

http /

SocialTag